List of Excipients in Branded Drug TONMYA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Tonix Medicines Inc	TONMYA	cyclobenzaprine hydrochloride	70792-102	CROSPOVIDONE
Tonix Medicines Inc	TONMYA	cyclobenzaprine hydrochloride	70792-102	D&C YELLOW NO. 10
Tonix Medicines Inc	TONMYA	cyclobenzaprine hydrochloride	70792-102	DIBASIC POTASSIUM PHOSPHATE
Tonix Medicines Inc	TONMYA	cyclobenzaprine hydrochloride	70792-102	MANNITOL

Tonmya Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

Tonmya is the proposed brand for TNX-102 SL, a low-dose sublingual formulation of cyclobenzaprine hydrochloride under development by Tonix Pharmaceuticals for fibromyalgia. Its commercial value depends on rapid sublingual disintegration, acceptable taste, dose uniformity at a low active load, and protection of the dosage form against conventional generic substitution. The formulation creates opportunities for specialty excipient suppliers, oral thin-tablet manufacturers, analytical laboratories, packaging providers, and contract development and manufacturing organizations.

Publicly available information does not establish an FDA-approved Tonmya label, final inactive-ingredient list, Orange Book listing, or approved patent-term extension. Commercial analysis should therefore focus on the formulation attributes required for a successful NDA and later generic competition.

What is Tonmya and how does the formulation work?

Tonmya is associated with TNX-102 SL, a sublingual tablet containing cyclobenzaprine hydrochloride. Tonix has studied the product as a bedtime treatment for fibromyalgia, with the intended profile of rapid dissolution in the oral cavity and systemic exposure from a low dose of cyclobenzaprine [1,2].

Attribute	Publicly reported or expected profile
Proposed brand	Tonmya
Development code	TNX-102 SL
Active ingredient	Cyclobenzaprine hydrochloride
Dosage form	Sublingual tablet
Development indication	Fibromyalgia
Administration	Bedtime sublingual administration
Commercial positioning	Low-dose, centrally acting treatment with a differentiated route of administration
FDA approval status	No approved Tonmya product identified in the public information reviewed
Orange Book status	No listed Tonmya product identified
Generic pathway	Likely dependent on an eventual ANDA, subject to final approved product characteristics

The product is designed to differ from conventional oral cyclobenzaprine tablets. Immediate-release oral cyclobenzaprine products are generally used for short-term muscle spasm treatment, while TNX-102 SL has been developed for chronic fibromyalgia treatment. The sublingual route may reduce reliance on gastrointestinal dissolution and create a distinct pharmacokinetic and patent profile.

What excipients are most important for a Tonmya sublingual tablet?

The central excipient problem is balancing fast disintegration with taste, mechanical strength, low dose uniformity, moisture control, and manufacturability. A practical formulation would likely use a directly compressible, water-soluble or partially soluble filler combined with a superdisintegrant, taste modifier, lubricant, and moisture barrier.

Candidate excipient functions

Formulation function	Candidate excipient classes	Commercial objective
Bulking agent	Mannitol, compressible sugars, microcrystalline cellulose	Provide tablet mass and mouthfeel
Rapid disintegration	Crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose	Shorten residence time and improve dispersion
Taste masking	Sweeteners, flavors, ion-exchange resin, polymer coating, cyclodextrin complex	Reduce bitterness and throat sensation
Binding	Povidone, copovidone, hydroxypropyl cellulose	Improve tablet strength at low compression force
Lubrication	Sodium stearyl fumarate, magnesium stearate, leucine	Support ejection without excessive hydrophobicity
Saliva interaction	Mucoadhesive polymers or low-level cellulose derivatives	Control residence time without creating a gummy texture
pH adjustment	Citrate, phosphate, carbonate or bicarbonate systems	Manage dissolution and perceived taste
Moisture control	Desiccant packaging, low-moisture excipients, protective blister films	Preserve hardness and disintegration
Flavor	Mint, citrus, berry or cooling systems	Improve acceptability during bedtime use

The excipient selection must account for the pharmacology of cyclobenzaprine. Because the active ingredient is potent relative to the tablet mass, content uniformity may be more difficult than in a conventional high-dose tablet. Geometric dilution, ordered mixing, spray deposition, granulation, or a carrier-based premix can reduce segregation.

Mannitol is commercially attractive because it provides a cooling mouthfeel, good compressibility in selected grades, and water solubility. It can also create a smoother oral sensory profile than some insoluble fillers. The main development risks are brittle tablets, sensitivity to compression conditions, and grade-specific behavior.

Microcrystalline cellulose can improve compactibility but may create a less elegant mouthfeel and slower dissolution if used at high levels. It is better suited to a blended system than as the sole filler when rapid sublingual performance is the primary claim.

Crospovidone is a strong candidate where rapid liquid uptake and tablet breakup are required. Croscarmellose sodium can also support rapid disintegration, although its swelling behavior may produce a more noticeable residue under the tongue. Low-substituted hydroxypropyl cellulose may support both disintegration and binding.

How should Tonmya manage cyclobenzaprine taste?

Taste masking is likely to be one of the highest-value excipient decisions. Cyclobenzaprine is an amine-containing compound, and sublingual delivery exposes the drug to taste receptors before swallowing. Conventional oral-film or orally disintegrating-tablet taste strategies may be insufficient if they delay drug release or increase tablet size.

Which taste-masking technologies fit Tonmya?

A practical development sequence would evaluate four approaches:

1. Sweetener and flavor system.
   Sucralose, acesulfame potassium, xylitol, mannitol, mint flavor, and cooling agents can improve acceptability. This is the lowest-cost and least complex option, but it may not adequately suppress bitterness.

2. Drug-resin complex.
   An ion-exchange resin can reduce immediate drug release in the mouth while allowing release after swallowing. The risk is that the complex may undermine the intended sublingual exposure or introduce content-uniformity and dissolution variability.

3. Polymer coating or microencapsulation.
   A thin coating around drug particles can reduce taste without changing the entire tablet matrix. Ethylcellulose, methacrylate copolymers, or other film-forming systems may be considered, subject to release and safety requirements.

4. Cyclodextrin complexation.
   Cyclodextrins can reduce free drug exposure at taste receptors and improve wetting. They add cost and may increase tablet mass, which is a material consideration for a sublingual product.

The strongest commercial formulation is likely to use a layered approach: a pleasant filler base, a low-level sweetener and flavor system, and a physical taste-masking technique if sensory testing shows that simple flavoring is inadequate.

What manufacturing process is best suited to Tonmya?

Direct compression is the most commercially efficient route if the selected excipients provide sufficient flow, compactibility, and content uniformity. It avoids solvent exposure and can reduce manufacturing costs. The process would require tight control of:

• Active-to-excipient premixing.
• Blend segregation.
• Tablet weight and hardness.
• Compression force.
• Friability.
• Disintegration time.
• Sublingual dissolution.
• Residual moisture.
• Cleaning validation for a potent, low-dose active.

Dry granulation is a potential alternative if the active or filler blend has poor flow. It can improve uniformity and compressibility without introducing water. Wet granulation is less attractive because moisture may affect cyclobenzaprine stability, tablet dissolution, or taste-masking coatings.

A multilayer tablet is technically possible but commercially less attractive unless it provides a clear benefit. A layered design could separate taste-masked drug particles from rapidly dissolving excipients or create a controlled dissolution interface. It would also increase tooling complexity, validation burden, and generic development cost.

What packaging is important for Tonmya?

Packaging is part of the excipient and product strategy because sublingual tablets can be highly sensitive to moisture and handling damage. Unit-dose alu-alu blister packaging is likely to offer the strongest combination of moisture protection, dose convenience, and patient adherence. Bottles with desiccants may be cheaper but create more exposure to humidity after opening.

The commercial package should prioritize:

• High moisture-barrier blister material.
• Child-resistant compliance where required.
• Easy peel or push-through performance.
• Protection against tablet abrasion.
• Clear instructions for sublingual placement.
• Stable performance across temperature and humidity conditions.

Packaging suppliers with pharmaceutical-grade cold-form foil, high-barrier lidding, and unit-dose automation have a direct opportunity if Tonmya advances toward approval.

What FDA regulatory status does Tonmya have?

Tonmya is not identified as an FDA-approved product in the established public information reviewed. TNX-102 SL has been evaluated in clinical studies for fibromyalgia, including a Phase 3 program reported by Tonix Pharmaceuticals [1,2].

Regulatory issue	Status
FDA-approved Tonmya label	Not identified
Approved inactive-ingredient statement	Not identified
Orange Book listing	Not identified
Approved generic product	None identified
FDA exclusivity expiration	Not established
Patent-term extension	Not established
Paragraph IV litigation	No verified Tonmya case identified
505(b)(2) or NDA pathway	Product-specific regulatory pathway would depend on the sponsor’s final submission

The lack of an approved label means that the final excipient system may change during late-stage development. The formulation selected for commercial scale must support the drug-product specifications, clinical performance, stability package, and regulatory justification for the sublingual route.

What patents protect Tonmya and its formulation?

The commercial protection for Tonmya is expected to rely primarily on formulation, dosage-form, method-of-use, and manufacturing claims rather than on the underlying cyclobenzaprine molecule, which is long established.

Potential claim categories include:

• Sublingual cyclobenzaprine compositions.
• Low-dose administration for fibromyalgia.
• Bedtime administration.
• Treatment of sleep disturbance associated with fibromyalgia.
• Rapid-disintegrating or rapid-dissolving tablet structures.
• Specific particle sizes or drug-excipient ratios.
• Taste-masked cyclobenzaprine compositions.
• Manufacturing processes that produce content uniformity.
• Packaging or moisture-control configurations.

Patent strength will depend on whether claims cover a commercially necessary feature or merely an optional formulation choice. A patent directed to a specific excipient ratio may be easier to design around than a patent covering the broader sublingual composition and therapeutic method.

How strong is the Tonmya patent estate?

The estate should be assessed across five dimensions:

Factor	Strategic relevance
Claim breadth	Determines whether generic developers can substitute excipients
Expiration timing	Sets the period of post-approval protection
Enablement support	Affects validity against written-description and enablement challenges
Clinical linkage	Determines whether method claims track the approved indication
Manufacturing dependence	Indicates whether a generic can reproduce performance without using the claimed process

Because Tonmya lacks a confirmed approved label and public Orange Book listing, a definitive expiration timetable cannot be assigned to the commercial product. The critical diligence items are published patent families, terminal disclaimers, continuation status, prosecution history, PTA, PTE, and any patent certifications filed after approval.

When could Tonmya lose exclusivity?

Tonmya could face several forms of competition:

1. Pre-expiration formulation design-arounds.
   A generic developer could use different fillers, disintegrants, taste-masking agents, or packaging if the claims are narrow.

2. Paragraph IV ANDA challenges.
   Once an NDA is approved and eligible patents are listed, an ANDA applicant could certify that listed patents are invalid, unenforceable, or not infringed.

3. Section viii carve-outs.
   A generic could seek approval for non-protected indications if the relevant method-of-use claims are listed and legally suitable for a labeling carve-out.

4. Competing cyclobenzaprine products.
   Existing oral cyclobenzaprine generics may remain substitutes even without duplicating the sublingual dosage form.

5. Alternative fibromyalgia therapies.
   Pregabalin, duloxetine, milnacipran, low-dose antidepressants, and nonpharmacologic treatment options create pricing pressure.

The principal generic barrier is likely to be bioequivalence and comparative performance, not the cost of the active ingredient. A generic developer may need to demonstrate sublingual dissolution, dose uniformity, pharmacokinetic equivalence, and acceptable sensory properties.

What commercial opportunities exist for excipient suppliers?

Tonmya creates a focused opportunity rather than a large-volume commodity opportunity. The highest-value suppliers will be those that can provide performance data, regulatory documentation, and formulation support.

Priority supplier opportunities

Directly compressible mannitol and co-processed fillers.
A supplier offering low-moisture, high-flow, orally acceptable grades can compete for the primary filler position.

Rapid-disintegration systems.
Crospovidone, croscarmellose sodium, and multifunctional co-processed excipients may be evaluated for short residence time and robust performance.

Taste-masking platforms.
Drug-resin complexes, coated microparticles, cyclodextrins, and proprietary flavor systems have the potential to generate higher margins than standard fillers.

Low-dose blending technologies.
Suppliers that provide premixes or carrier-based systems can address cyclobenzaprine content uniformity and reduce manufacturing risk.

Moisture-barrier packaging.
Unit-dose blister suppliers can capture value even if the formulation uses conventional excipients.

Analytical and sensory services.
In vitro dissolution, saliva-mimicking testing, electronic tongue analysis, and human taste panels are important development services for the product class.

How does Tonmya compare with existing fibromyalgia drugs?

Product or class	Route	Main differentiation	Generic pressure
Tonmya/TNX-102 SL	Sublingual	Bedtime, low-dose cyclobenzaprine formulation	No approved generic product identified
Pregabalin	Oral	Neuropathic pain and fibromyalgia indication	Generic available
Duloxetine	Oral	Fibromyalgia, depression, anxiety and pain indications	Generic available
Milnacipran	Oral	Fibromyalgia indication	Generic pressure exists
Conventional cyclobenzaprine	Oral	Muscle spasm treatment	Generic available

Tonmya’s commercial case depends on demonstrating that the sublingual route and bedtime dosing produce a clinically meaningful benefit over existing generic therapies. A higher price would require evidence of improved sleep, tolerability, adherence, pain reduction, or reduced next-day impairment.

What licensing and partnership opportunities exist?

Publicly identified commercial value is concentrated in Tonix’s internal development program. The most plausible partnership structures include:

• Regional licensing for fibromyalgia markets outside the United States.
• Co-development with a specialty pain or central nervous system company.
• Supply agreements with a sublingual-tablet CDMO.
• Preferred-excipient agreements tied to formulation performance.
• Packaging partnerships for unit-dose blister production.
• Post-approval lifecycle licensing for additional sleep or pain indications.

Excipient suppliers should seek design-in status before pivotal commercial batches are locked. Once a supplier’s grade is embedded in the validated process and regulatory dossier, replacement becomes more difficult because of comparability, stability, dissolution, and sensory testing requirements.

What generic launch risks exist for Tonmya?

The strongest generic launch scenario would use a different excipient system while matching the reference product’s critical quality attributes. Key risks include:

• A broad patent claim covering the sublingual composition.
• Difficult-to-reproduce taste-masking performance.
• A narrow bioequivalence window caused by rapid absorption.
• Lack of public information on the final reference formulation.
• High sensory-testing burden.
• Product-specific device or blister requirements.
• Clinical uncertainty regarding the commercial indication.
• Limited market size relative to development costs.

The most defensible innovator position would combine broad composition claims, clinically linked method-of-use claims, robust formulation patents, and a commercial product with measurable patient benefits. A single narrow patent covering one excipient ratio would provide less durable protection.

Key Takeaways

• Tonmya is associated with TNX-102 SL, a sublingual cyclobenzaprine hydrochloride product being developed for fibromyalgia.
• The primary excipient challenges are rapid disintegration, taste masking, low-dose content uniformity, tablet strength, and moisture stability.
• Mannitol, crospovidone, croscarmellose sodium, low-moisture binders, sweeteners, flavor systems, and protective blister packaging are logical development targets.
• Taste-masking technology may be the highest-value formulation differentiator.
• Tonmya does not have an identified approved FDA label, Orange Book listing, or approved generic product in the public information reviewed.
• Commercial exclusivity is likely to depend on sublingual formulation, method-of-use, manufacturing, and packaging claims rather than cyclobenzaprine composition-of-matter protection.
• Excipient suppliers and CDMOs have the strongest opportunity before commercial formulation lock and pivotal-scale manufacturing.
• Generic risk will depend on claim breadth, bioequivalence requirements, taste performance, and the ability to design around protected excipient combinations.

FAQs

What is the likely best filler for a Tonmya sublingual tablet?

Mannitol is a leading candidate because it offers water solubility, a cooling mouthfeel, and compatibility with orally disintegrating systems. The final choice depends on tablet strength, dissolution, moisture stability, and sensory testing.

Could Tonmya use a conventional cyclobenzaprine tablet formulation?

A conventional oral tablet would not necessarily reproduce the performance or clinical positioning of a sublingual product. Generic developers would need to match the approved reference product’s route, dosage form, quality attributes, and bioequivalence requirements.

Are taste-masking excipients likely to be patent-protected?

They can be. Protection may cover the specific drug-excipient complex, coating, particle structure, polymer system, or composition ratio rather than the individual excipient itself.

What is the largest formulation risk for Tonmya?

The largest risk is achieving strong taste masking without slowing sublingual release or increasing tablet size. Excessive coating, resin binding, or polymer content can impair the intended absorption profile.

Can excipient suppliers obtain commercial exclusivity for Tonmya?

An excipient supplier generally would not receive pharmaceutical-product exclusivity solely by supplying a standard excipient. Commercial leverage is stronger when the supplier provides a proprietary grade, taste-masking system, co-processed platform, validated premix, or formulation technology incorporated into the sponsor’s regulatory dossier.

References

1. Tonix Pharmaceuticals Holding Corp. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

2. ClinicalTrials.gov. (2024). A study of TNX-102 SL in participants with fibromyalgia syndrome: RESILIENT study. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA and Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. U.S. Department of Health and Human Services.